Current Problems in Cardiology 49 (2024) 102722

Contents lists available at ScienceDirect

Current Problems in Cardiology

journal homepage: www.elsevier.com/locate/cpcardiol

Prevention of cardiotoxicity in childhood cancer survivors: In physical exercise, we trust

Valentina Bucciarelli [a,*], Francesco Bianco [a], Giandomenico Bisaccia [b], Kristian Galanti [b], Allegra Arata [b], Mirella Ricci [b], Benedetta Bucciarelli [c], Michele Marinelli [c], Giulia Renda [b], Alberto Farinetti [d], Anna Vittoria Mattioli [e,f], Sabina Gallina [b]

[a] Cardiovascular Sciences Department, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy
[b] Department of Neuroscience, Imaging and Clinical Sciences, University of Chieti-Pescara, 66100 Chieti, Italy
[c] Department of Pediatrics, Marche Polytechnic University, 60123 Ancona, Italy
[d] Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, 41121 Modena, Italy
[e] Istituto Nazionale per le Ricerche Cardiovascolari, 40126 Bologna, Italy
[f] Department of Quality of Life Sciences, University of Bologna, 40126 Bologna, Italy

ARTICLE INFO

Keywords:
Childhood cancer survivors (CCS)
Cancer therapy-related cardiovascular toxicity (CTR-CVT)
Chemotherapy (CHT)
Radiotherapy (RT)
Physical exercise (PE)

ABSTRACT

In recent years, the mean survival rate of children after a cancer diagnosis has significantly improved. At the same time, a growing interest in short and long-term cardiovascular (CV) complications of cancer therapy, as well as long-term CV risk in childhood cancer survivors (CCS) developed, along with proposals of protocols for the diagnosis, management, and prevention of cancer therapy-related CV toxicity (CTR-CVT) in this population. Many clinical and individual risk factors for CTR-CVT have been identified, and a non-negligible prevalence of traditional CV risk factors has been described in this population, potentially associated with a further worsening in both CTR-CVT and long-term CV risk. Physical exercise (PE) represents a promising, free-of-cost and free-of-complications, helpful therapy for primary and secondary prevention of CTR-CVT in CCS. The present narrative review aims to summarize the most critical evidence available about CTR-CVT in CCS, focusing on the role of PE in this clinical scenario.

Introduction

Cancer represents the main disease-related cause of death in pediatrics, with 400,000/year children and teenagers facing a malignancy diagnosis.[1,2] Cancer management innovations upgraded the 5-year survival rate, in this population, reaching 40-to-80% in

Abbreviations: ALL, acute lymphocytic leukemia; ANT, anthracyclines; CCS, childhood cancer survivors; CMR, cardiac magnetic resonance; CPET, cardiopulmonary test; CRF, cardiorespiratory fitness; CTR-CVT, cancer therapy-related cardiovascular toxicity; CV, cardiovascular; CVD, cardiovascular disease; ECG, electrocardiogram; GLS, global longitudinal strain; HF, heart failure; LV, left ventricular; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; PA, physical activity; PE, physical exercise; PI, physical inactivity; QoL, quality of life; RT, radiotherapy; TDI, tissue Doppler imaging; TTE, thansthoracic echocardiography.

* Corresponding author at: Cardiovascular Sciences Department, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126, Ancona (AN), Italy.
E-mail address: valentina.bucciarelli@ospedaliriuniti.marche.it (V. Bucciarelli).

https://doi.org/10.1016/j.cpcardiol.2024.102722

Available online 20 June 2024

low and high-income countries, respectively.[3]

Neverthless, childhood cancer survivors (CCS) are at risk for short and long-term complications: cancer recurrences and functional impairments, mainly. Besides, they will also experience further complications within 30 years from their diagnosis, including cancer therapy-related CV toxicity (CTR-CVT).[4] Data from the CCS study reports an overall mortality rate 8.4 times higher than that of healthy controls, with a 40-year cumulative all-cause mortality of 23.3%.[5–7] CCS experience a 2-to-10-fold increase in overall CV risk compared to the general population and a 7-fold increase in CV-related mortality, with substantial psycho-physical and economic issues, leading to a decreased quality of life (QoL), especially in females.[8–13] Furthermore, frailty, defined as a condition associated with reduced physiologic reserve that is generally documented in older adults, represents an emerging, relevant issue in young adult CCS, with a prevalence among 7.9% that is comparable to that of 9.9% reported in older adults in the general population.[14,15] Frailty itself determines a lower physiologic reserve and decreased physical fitness levels, leading to an increased risk of chronic disease, including CV disease (CVD) and mortality in CCS.

As CVD constitutes the second cause of premature mortality in CCS, after cancer itself, primary and secondary CV prevention in this population is imperative, especially when considering the strong correlation linking CV risk, mental issues, QoL, chronic inflammatory and pro-oxidant status, and cancer.[7,16] In this regard, the strong association between poor mental health and CV risk factors, such as sedentarism, PI, and weight gain, should always be kept in mind, especially in CCS, which generally report symptoms of depression and require specific medical therapy more frequently than controls.[17,18] Moreover, in CCS, there is an increased risk of post-traumatic stress disorder, which is, in turn, strongly associated with CV risk factors, and CV mortality.[19] In addition to the need to improve event-free and overall survival in these patients, these findings support the necessity to focus on late CV effects and QoL in CCS. In this setting, PE represents a crucial tool in CV risk factors prevention and treatment, gaining pro-oxidant status reduction and QoL improvement and working on primary and secondary prevention of CRT-CVT as well (Fig. 1).[20]

In line with the recommendations for cardiomyopathy surveillance for CCS, published by the Childhood Cancer Guideline Harmonization Group, regular PE should be prescribed in every survivor treated with anthracyclines or chest radiation, who have normal left ventricular (LV) systolic function. On the other hand, a cardiology consultation should be prescribed for survivors with asymptomatic cardiomyopathy or for high-risk survivors to delineate the risk type and amount for exercise. However, to date, no specific indications are available regarding specific PE protocols for each patient in terms of type, duration, amount of PE, and monitoring of potential adverse or beneficial effects.[21] The aim of the present narrative review is to offer an updated review of the most critical evidence available about the role of PE in this clinical scenario. We searched MEDLINE, Scopus and Web of Science, using a combination of terms relating to childhood cancer survivors (eg, cancer; pediatrics; childhood cancer survivors), cardiotoxicity (cancer therapy-related cardiovascular toxicity; cardiotoxicity; chemotherapy; radiotherapy; primary prevention; secondary prevention; follow-up**)** and physical exercise (eg, physical activity; physical exercise).

Pathophysiology of cardiotoxicity in childhood

Significant improvements in managing oncologic diseases, including prompt diagnosis and treatment, led to a sensible increase in patient long-term survival and QoL in the last decades. Prolonged life expectancy among CCS also led to a rise in the prevalence of the comorbidities that may occur because of cancer therapy administration, which from a CV perspective are comprehensively referred to with the term CTR-CVT. The variety and severity of CTR-CVT depend on the type and dosage of the drug administered in a particular patient. Acute and early-onset CTR-CVT in children includes therapy-related cardiomyopathy (transient or progressive), myocarditis, pericarditis, arrythmias, and vascular complications.[22,23] Clinical risk factors associated with more severe CTR-CVT are considered: higher lifetime cumulative doses of ANT with greater dose rates, younger age at treatment, longer follow-up after treatment, female sex, chest RT, CV risk factors.[24–26]

There is a substantial heterogeneity in the definition of cardiotoxicity due to childhood cancer treatment, based on the combination



Fig. 1. Physical exercise in primary and secondary CV prevention in childhood cancer survivors (CCS). CCS experience an increased long-term risk of cardiovascular diseases (CVD) that is influenced by cancer-therapy related cardiovascular toxicity (CTR-CVT), radiation exposure, chronic inflammatory status related to cancer itself, fatigue and sedentarism and traditional CV risk factors as well (arterial hypertension, dyslipidemia, altered glucose metabolism, mental health issues, genetic predisposition). Physical exercise can play a relevant role in primary and secondary prevention of CTR-CVT, reducing CV risk factors prevalence and impact, improving chronic inflammatory and pro-oxidant status associated with cancer and its related therapies, and enhancing cardiorespiratory fitness and short and long-term risk of CVD.

of echocardiographic data, clinical indicators and biomarkers.[27] Therapy-related cardiomyopathy can be described as a decline in cardiac function, either following cardiomyocyte damage, alterations of myocardial perfusion, hormonal/autonomic nervous system imbalance, or inflammatory response leading to myocardial infiltration of immune cells yielding myocardial fibrosis.[28] Despite specific, less-detrimental formulations have been developed, this complication is still relevant and there may be no harmless ANT dose.[29] High-dose ANT (> 250 mg/m2) and exposure to chest RT > 15 Gy are established risk factors for CTR-CVT, but even survivors who received a mean chest RT dose of 5 to 15 Gy or a cumulative ANT dose of 100-250 mg/mq have an increased risk of heart failure (HF).[30] In children, aside from symptomatic HF, ANT-related cardiotoxicity can frequently manifest as subclinical troponin elevation related to myocardial injury, due to an excessive production of free radicals, the inhibition of the topoisomerase II enzyme, and an iron/-calcium homeostasis imbalance.[29] Chronic ANT-related cardiotoxicity is characterized by histological changes, leading to cell loss and fibrosis.[31] Other conventional chemotherapeutics, such as alkylating agents, platinum, differentiating agents, and antimetabolites, being associated to arrhythmias, myocardial ischemia, hypertension and dyslipidemia in adults, are less frequently associated with cardiotoxicity in pediatrics. Although the development of targeted therapies aimed to reduce CTR-CVT, both on- and off-target cardiotoxicity has been reported, and the use of immune checkpoint inhibitors has been related to rare, mostly reversible cases of myocarditis.[22] Finally, cardiotoxicity could be influenced by genetic variability regarding the metabolic pathways of chemotherapeutics.[22]

Diagnosis of cardiotoxicity in childhood: from imaging to cardiac biomarkers

Non-invasive tests

Electrocardiogram (ECG)

The ECG can identify early signs of cardiotoxicity, e.g. resting tachycardia, ST-T wave abnormalities, conduction disorders, prolonged QT interval, or arrhythmias. These findings are non-specific and may be unrelated to CTR-CVT. Furthermore, as they are often reversible, the use of 24-hours Holter monitoring may be needed to assess any dynamic changes in cardiac conduction.[32]

Cardiopulmonary exercise testing (CPET)

CPET may represent a first-line tool to detect subclinical cardiac dysfunction in CCS, with reduced peak oxygen consumption and exercise capacity being related to previous exposure to ANT.[33,34] To date, the research landscape on CPET in the workup of CCS is still sparse and based on retrospective studies.

Imaging

Echocardiography

Two-dimensional transthoracic echocardiography (TTE) is the most widely used method for evaluating CTR-CVT in children. As standard TTE parameters have a low predictive value in identifying cardiotoxicity, the use of global longitudinal myocardial strain (GLS) and Tissue Doppler Imaging (TDI) has been strongly, routinely recommended in both adult and CCS since they allow earlier identification of myocardial damage.[35–39] Studies regarding the use of three-dimensional TTE in pediatrics are ongoing.[40]

Cardiac magnetic resonance imaging (CMR)

The use of CMR to monitor CTR-CVT in children has been sparsely investigated.[41,42] On a general note, due to limited availability, long procedural times, and high cost, CMR is not routinely recommended in the workup of CCS; however, it could become the screening modality in high risk patients with poor-quality echocardiographic images or pre-existing CVD.[43]

Biomarkers

Serum cardiac troponin

An acute increase in serum troponin levels following ANT in children with acute lymphocytic leukemia (ALL), due to cardiac cell damage, has been demonstrated.[44] However, no definite data support a strong association between troponin release and LV dysfunction in CCS.[45,46]

Natriuretic peptides

N-terminal pro-brain natriuretic peptide (NT-proBNP) has been used to predict early cardiotoxicity in children with ALL, before the onset of pathological LV remodeling.[47] Nevertheless, as for its low sensitivity, it has to be appraised in the context of clinical assessment and TTE.[48]

D-Dimer

D-dimer represents a marker for deep vein thrombosis and pulmonary embolism, with high negative predictive value and poor specificity.[49] Thus, it is recommended to use D-Dimer levels only to rule out suspected venous thromboembolism, and no evidence supports its use for CTR-CVT or survival estimate in CCS.

Others

Several potential cardiotoxicity biomarkers, such as C-reactive protein, growth/differentiation factor 15, myeloperoxidase, placental growth factor, soluble Fms-like tyrosine kinase receptor 3, and galectin 3, have been recently investigated.[50] However, they significantly changes only after heart damage occurs, with uncertain incremental value in CTR-CVT. Omics science, comprising genomics, transcriptomics, proteomics, and metabolomics, is investigating their possible integration in the workup of CCS.[51]

Management of CTR-CVT in childhood

The management of CCS encompasses CTR-CVT prevention, pharmacological approaches, and implementation of PE interventions. Primary prevention strategies include RT exposure reduction protocols and cardioprotective antineoplastics' formulations, the latter being experimented in different randomized controlled trials.[52] To date, only dexrazoxane (DRZ) received Food and Drug Administration and European Medicines Association approval in adults as a cardio-protectant agent and recently it showed to play a significant cardioprotective effect in young adult-aged CCS nearly 20 years after ANT exposure.[53–57] Enalapril demonstrated cardiac function improvement in patients treated with ANT high-doses, whereas the latest data from literature do not support the administration of carvedilol for secondary HF prevention in CCS after ANT exposure. The use of statins in the same scenario is under study.[22,58–60] Other potential, long-term, CV side effects in CCS include arterial hypertension, dyslipidemia, glucose intolerance, and adiposity. Cranial, abdominal, and total body irradiation represent specific risk factors for metabolic dysfunction. Nephrectomy, abdominal irradiation, and antineoplastic alkylating agents can contribute to nephrotoxicity. The epidemiological and clinical manifestations of these complications will be defined in the KINDEST-CCS and the Dutch LATER METS studies.[61–63] According to the specific clinical history and risk factors, each CCS should undergo periodic laboratory tests to monitor cardio-nephro-metabolic parameters and serial ambulatory blood pressure evaluation. Furthermore, lifestyle factors management, focused on PE and balanced diet, should be warranted, despite the lack of research on the PE and nutritional interventions for CCS, with no adequate recommendations about the usefulness of dietary interventions in this population.[64,65]

Prevention of CTR-CVT in childhood: the paramount role of physical exercise

CV risk factors and CTR-CVT vs exercise intervention in CCS

Successful management in CCS requires a multidisciplinary approach in which caregivers, health professionals, and patients cooperate to pursue children's short and long-term health. CCS experience a two-to-tenfold increase in overall CV risk compared to the general population and a 7-fold increase in mortality due to CV complications, such as severe LV dysfunction or sudden cardiac death, with the prevalence of CV risk factors significantly increasing with time.[9,25,66] CCS exhibit a higher risk for future CVD even when compared with a non-cancer age-, sex-, and ethnicity-matched control population with similar cardiometabolic profiles, with a probability of 3% and 10% of developing CVD, respectively, at 30 and 45 years of age.[66,67] Moreover, they suffer from a significant burden of modifiable CV risk factors at an earlier age than the general population, and this burden significantly increases with time, enhancing more than 5-fold their risk of severe CVD.[7,11,25,66,68,69] We must keep in mind that cancer and CVD share common traditional and novel risk factors, and antineoplastic therapies, along with health behavioral changes and psychological issues, negatively impact CV risk.[70–74] These considerations warrant the need for CCS to undergo long-term clinical follow-up and lifestyle assessment.[75] CV risk factors in CCS are generally underdiagnosed and undertreated, whereas they could be counteracted by effective PE interventions, with a significant mortality reduction.[7,22,76] PI represents a weighty modifiable CV risk factor in CCS, as it affects more than 70% of CCS and is associated with a higher cardiometabolic burden.[70, 77, 78] While anxiety, fatigue, and lack of motivation may explain this deteriorating attitude, it is also likely that CV prevention campaigns do not systematically target these patients, which are easily lost to follow-up.[71,72] CCS significantly reduce the total amount and the average time spent in PA, especially in moderate-to-vigorous PA, negatively impacting cardiorespiratory fitness (CRF) .[79–81] CRF represents an essential health indicator in youth and a primary prognostic marker of survival and CV risk in CCS.[82,83]

On the other hand, regular exercise training exerts its cardioprotective mechanisms in cancer patients in several ways. Firstly, it increases cardiac muscle adaptation and growth, reducing cardiomyocyte apoptosis and improving cardiovascular reserve in terms of better endothelial and autonomic function and cardiac perfusion. Secondly, it reduces inflammatory markers and endogenous stress, ameliorating antioxidant status. Thirdly, it improves cardiometabolic risk profile in terms of reduced CV risk burden, counteracting sarcopenic effects of anticancer treatment, and ameliorating CRF during and after treatment in children.[84–92] High PA ($\geq$ 60 minutes per day of moderate-to-vigorous PA) in CCS improves cardiometabolic profile in terms of fat mass reduction and lowers CV risk at a long-term follow-up, as compared to low PA.[93] Conversely, low PA, high screen time, old age, female gender, and high waist-to-height ratio represent predictive factors for worse CRF.[94]

In CCS, the cumulative incidence of CV events is inversely correlated with the increase in the reported PE levels, with a 10-year incidence of CV events of 12.2% for survivors reporting a low exercise exposure compared with 5.2% for those describing adherence to vigorous-intensity PE.[95] Moreover, $\geq$ 2.5 hours of intense PA/week for at least one year can determine a substantial CVD risk score reduction.[96]

Exercise guidelines for CCS following antineoplastic treatments have been published, but compared to literature evidence in adults, cardioprotective properties of PE in CCS have received less attention. There is a significant heterogeneity among the available studies in terms of patients' characteristics, exercise protocols, and the time interval between cancer diagnosis and therapy, and exercise prescription.[97–99] A Cochrane systematic review by Braam et al., including 171 CCS, undergoing a PE training program within the first

five years following the diagnosis of a childhood cancer, demonstrated that although some positive results were found in terms of CRF, body composition, and QoL, the overall data were inadequate due to the heterogeneous study methodology regarding the number of participants and the characteristics of the exercise intervention.[100] Analogously, Bourdon et al. demonstrated that aerobic PE determines a statistically and clinically significant positive effect of CRF in CCS when compared to the change in CRF experienced by a control, standard-of-care group.[101] The same Authors underlined that the impact of aerobic PE training on CRF seems to be less significant among CCS as compared to adult cancer survivors, as for the adverse effects of cancer itself and related therapies on physiological growth and development, and for the lower adherence to PE experienced by CCS.[102] Furthermore, they highlighted the meaningful heterogeneity of clinical characteristics and intervention parameters across the available studies, thus supporting the need for more high-quality randomized controlled trials in this clinical scenario. Recently, Kendall et al. published the first scoping review exploring the impact of PE on the development of CTR-CVT in CCS. The authors included six reports, carried out from 1993 to 2020, that significantly varied according to patients' characteristics, PE protocol, and impact of PE on CTR-CVT.[103–108] Regarding PE interventions, one study included only aerobic PE, whereas the other five entered a combination of aerobic and resistance training; moreover, the PE protocol was administrated during cancer treatment in one study and 4- to-30 years after the diagnosis in the other reports and none met the current World Health Organization's guidelines exercise standards for CCS (2.5 hours/week of aerobic exercise for adults and strength training twice a week for adults; 1h/day of aerobic exercise and strength training twice a week for children).[109] The cancer diagnosis and the CV health-related findings significantly differed among the studies. However, all reports suggested the benefit of PE in mitigating CTR-CVT risk in CCS.[110] Finally, an umbrella review by Rapti et al., including 13 studies, provided a comprehensive overview of the positive effects of PE on many CV health outcomes in CCS, especially in terms of CRF, LVEF, and endothelial function, describing a limited number of adverse effects, even when exercise intervention was provided during hospitalization.[111–115]

One final consideration is that it seems that CCS do not benefit from regular PA as much as it happens in the non-cancer population. Firstly, ANT and RT interfere with mechanisms of CV adaptation to PA causing premature myocyte and cardiac progenitor cells apoptosis, thus limiting the physiological process of PA-related cardiac hypertrophy. Secondly, cancer therapies affect many cardiac and vascular adaptative mechanisms to PA, particularly endothelial function. These mechanisms decrease CCS physiological reserve as compared to the cancer-free population, with a potential increased risk of age-related chronic conditions. These considerations underline the need for more research to understand why CCS react differently than their peers to exercise training and to define which specific exercise interventions could amplify CV health benefits in this population.[116]

Future perspectives

Given these premises, trials are ongoing to enhance our understanding of the positive effects of PE on CTR-CVT in CCS.[92]

The HIMALAYAS Trial (NCT05023785) will provide data about the most effective PE prescription for CCS at risk of cardiotoxicity, comparing a strategy of cardio-oncology rehabilitation to standard of care concerning many outcomes of cardiac function.[75]

The BEACON (BEing Active after ChildhOod caNcer) study aims to create a person-centered, evidence-based intervention for promoting and supporting sustainable PA behavioral change in CCS, identifying the barriers and facilitators to PA in CCS.[117] In the LIFE Cancer Survivorship and Transition Program (Children's Hospital, Los Angeles) specific and practical evidence-based PE recommendations in CCS have been developed.[118]

PE protocols should be tailored for each patient, and periodically re-evaluated, based on CPET parameters and specific short and long-term effects of cancer therapy, to ensure the patient's safety and adherence to exercise.[118,119]

We must face, identify, and treat the causes of the "PI pandemic" in CCS to increase their adherence to exercise prescription. Three orders of factors influence PA participation among cancer patients: physiologic factors, psychosocial and cultural factors, environmental and economic factors.[120] Physiologic issues are related to cancer itself or to treatment-related side effects, such as cancer-related fatigue that has a prevalence of 0-62% and a multifactorial etiology, and lack of PA engagement.[121,122] Psychosocial features include low self-esteem and lack of motivation, whereas financial hardship and inaccessible services are among economic and environmental factors. According to the COG guidelines, clinicians should be aware about the psychosocial late effects experienced by CCS, with an active referral to mental health services and a tailored socioeconomic risk assessment.[98] These factors should be accurately screened and treated in CCS, and an accurate motivational lifestyle counseling should be offered.[122] Parental support, as well as the role of nurse-led intervention in early CV prevention and motivational interviewing with parents, should always be advocated in this context.[123–125] Both mHealth (medical and public health practice supported by mobile devices) and eHealth (the use of communication tools to upgrade health care) might play a relevant role among CCS.[126]

The PanCareFollowUp Consortium identified lack of time, unhealthy environment, and social media, as barriers to health behavior adherence in CCS and is gathering data about the feasibility and effects of an eHealth intervention to support sustainable PA and nutritional changes in CCS.[127,128] The PACCS study aims to broaden the available knowledge about the physiological, psychological, and social barriers to exercise that can be targeted in interventions to contribute to the development of an evidence-based PA intervention for young CCS to increase their long-term adherence to rehabilitation programs.[129]

Finally, the gender disparity in PA, especially in childhood and adolescence, must be considered, as in most countries girls are less physically active than boys, with a consequent additional increase in PI into adulthood, significantly impacting short and long-term CV health of women and offspring.[130–132] As female CCS experience a greater risk of maternal CV outcomes compared to general pregnancy, being greatly influenced by CV risk factors, especially PI, concrete attention must be paid to raising awareness of PE in the female CCS population.[133]

Conclusions

Substantial advances in cancer management have considerably upgraded the survival rate of CCS. However, these patients are still at risk of short and long-term complications. The effects of PE improving QoL, fatigue, and functional capacity in CCS have been demonstrated. However, to date, there are still poor data regarding the role of PE in primary and secondary prevention of CVT-CTR, the best PE training program for children with active cancer and CCS and the clinical characteristics of patients who can benefit the most from PE program. Future studies should include a higher number of participants affected by different cancer diagnoses; consider analogous material and methods and comparable PE training programs, defining the right time interval between cancer diagnosis and therapy and exercise prescription; identify the proper protocol of PE for the right patient in terms of type and duration of training, to ameliorate cardio-metabolic outcomes in CCS; highlight the clinical and social risk factors for PI and gender disparity in PA involvement in CCS; focus on personalized PA components and tailored PE programs supporting behavior change methods to decrease CV risk, amplify CV health and QoL as well, reducing long-term CV risk and CV morbidity and mortality[133]

Ethics approval

This article does not contain any studies with human participants or animals performed by any of the authors.

CRediT authorship contribution statement

Valentina Bucciarelli: Conceptualization, Data curation, Investigation, Methodology, Project administration, Validation, Visualization, Writing – original draft, Writing – review & editing. **Francesco Bianco:** Conceptualization, Investigation, Software, Writing – original draft. **Giandomenico Bisaccia:** Data curation, Investigation, Writing – original draft. **Kristian Galanti:** Investigation, Writing – original draft. **Allegra Arata:** Investigation, Writing – original draft. **Mirella Ricci:** Investigation, Writing – original draft. **Benedetta Bucciarelli:** Investigation, Writing – original draft. **Michele Marinelli:** Investigation, Writing – original draft. **Giulia Renda:** Formal analysis, Supervision, Writing – review & editing. **Alberto Farinetti:** Formal analysis, Funding acquisition, Resources, Supervision, Writing – review & editing. **Anna Vittoria Mattioli:** Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Resources, Supervision, Validation, Writing – review & editing. **Sabina Gallina:** Conceptualization, Formal analysis, Methodology, Project administration, Resources, Supervision, Validation, Writing – review & editing.

Declaration of competing interest

The authors declare there is no conflict of interests.

Funding

The authors declare that no funds, grants or other support were received during the preparation of this manuscript.

References

1. World Health Organization. *CureAll framework. WHO Global Initiative for Childhood Cancer: Increasing Access, Advancing Quality, Saving Lives. Geneva. Geneva*. 2021.
2. Wu Y, Deng Y, Wei B, et al. Global, regional, and national childhood cancer burden, 1990–2019: an analysis based on the Global Burden of Disease Study 2019. *J Adv Res*. 2022;40:233–247.
3. Bhakta N, Force LM, Allemani C, et al. Childhood cancer burden: a review of global estimates. *Lancet Oncol*. 2019;20(1):e42–e53.
4. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. *N Engl J Med*. 2006;355(15):1572–1582.
5. Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the childhood cancer survivor study. *JNCI*. 2008;100(19):1368–1379.
6. Reulen RC. Long-term cause-specific mortality among survivors of childhood cancer. *JAMA*. 2010;304(2):172.
7. Dixon SB, Liu Q, Chow EJ, et al. Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. *Lancet North Am Ed*. 2023;401(10386):1447–1457.
8. Bucciarelli V, Caterino AL, Bianco F, et al. Depression and cardiovascular disease: the deep blue sea of women's heart. *Trends Cardiovasc Med*. 2020;30(3):170–176.
9. Khanna A, Pequeno P, Gupta S, et al. Increased risk of all cardiovascular disease subtypes among childhood cancer survivors. *Circulation*. 2019;140(12):1041–1043.
10. Frederiksen LE, Erdmann F, Mader L, et al. Psychiatric disorders in childhood cancer survivors in Denmark, Finland, and Sweden: a register-based cohort study from the SALiCCS research programme. *Lancet Psychiatry*. 2022;9(1):35–45.
11. Ernst M, Hinz A, Brähler E, et al. Quality of life after pediatric cancer: comparison of long-term childhood cancer survivors' quality of life with a representative general population sample and associations with physical health and risk indicators. *Health Qual Life Outcomes*. 2023;21(1):65.
12. Nathan PC, Henderson TO, Kirchhoff AC, Park ER, Yabroff KR. Financial hardship and the economic effect of childhood cancer survivorship. *J Clin Oncol*. 2018;36(21):2198–2205.
13. Brinkman TM, Zhu L, Zeltzer LK, et al. Longitudinal patterns of psychological distress in adult survivors of childhood cancer. *Br J Cancer*. 2013;109(5):1373–1381.
14. Ness KK, Krull KR, Jones KE, et al. Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the St Jude lifetime cohort study. *J Clin Oncol*. 2013;31(36):4496–4503.
15. Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. *J Am Geriatr Soc*. 2012;60(8):1487–1492.
16. Rossi F, Di Paola A, Pota E, et al. Biological aspects of inflamm-aging in childhood cancer survivors. *Cancers*. 2021;13(19):4933.

17. Deyell RJ, Lorenzi M, Ma S, et al. Antidepressant use among survivors of childhood, adolescent and young adult cancer: A report of the childhood, adolescent and young adult cancer survivor (CAYACS) research program. *Pediatr Blood Cancer*. 2013;60(5):816–822.
18. Zebrack BJ, Zeltzer LK, Whitton J, et al. Psychological outcomes in long-term survivors of childhood leukemia, Hodgkin's disease, and Non-Hodgkin's lymphoma: a report from the childhood cancer survivor study. *Pediatrics*. 2002;110(1):42–52.
19. Stuber ML, Meeske KA, Krull KR, et al. Prevalence and predictors of posttraumatic stress disorder in adult survivors of childhood cancer. *Pediatrics*. 2010;125(5): e1124–e1134.
20. Thomas R, Kenfield SA, Yanagisawa Y, Newton RU. Why exercise has a crucial role in cancer prevention, risk reduction and improved outcomes. *Br Med Bull*. 2021;139(1):100–119.
21. Ehrhardt MJ, Leerink JM, Mulder RL, et al. Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Lancet Oncol*. 2023;24(3): e108–e120.
22. Chow EJ, Leger KJ, Bhatt NS, et al. Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment. *Cardiovasc Res*. 2019;115(5):922–934.
23. Hegazy M, Ghaleb S, Das B. Diagnosis and management of cancer treatment-related cardiac dysfunction and heart failure in children. *Children*. 2023;10(1):149.
24. Bansal N, Amdani S, Lipshultz ER, Lipshultz SE. Chemotherapy-induced cardiotoxicity in children. *Expert Opin Drug Metab Toxicol*. 2017;13(8):817–832.
25. Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. *J Clin Oncol*. 2013;31 (29):3673–3680.
26. Lipshultz SE, Adams MJ, Colan SD, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions. *Circulation*. 2013;128(17):1927–1995.
27. Kouwenberg TW, van Dalen EC, Feijen EAM, et al. Acute and early-onset cardiotoxicity in children and adolescents with cancer: a systematic review. *BMC Cancer*. 2023;23(1):866.
28. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. *Nat Rev Cardiol*. 2020;17(8):474–502.
29. Mele D, Tocchetti CG, Pagliaro P, et al. Pathophysiology of anthracycline cardiotoxicity. *J Cardiovasc Med*. 2016;17:e3–11.
30. de Baat EC, Feijen EAM, Reulen RC, et al. Risk factors for heart failure among pan-european childhood cancer survivors: A PanCareSurFup and ProCardio cohort and nested case-control study. *J Clin Oncol*. 2023;41(1):96–106.
31. Cascales A, Pastor-Quirante F, Sánchez-Vega B, et al. Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms. *Oncologist*. 2013;18(4):446–453.
32. Curren V, Dham N, Spurney C. Diagnosis, prevention, treatment and surveillance of anthracycline-induced cardiovascular toxicity in pediatric cancer survivors. *Hearts*. 2021;2(1):45–60.
33. Wolf CM, Reiner B, Kühn A, et al. Subclinical cardiac dysfunction in childhood cancer survivors on 10-years follow-up correlates with cumulative anthracycline dose and is best detected by cardiopulmonary exercise testing, circulating serum biomarker, speckle tracking echocardiography, and tissue doppler imaging. *Front Pediatr*. 2020:8.
34. Tsuda T, Kernizan D, Glass A, D'Aloisio G, Hossain J, Quillen J. Cardiopulmonary exercise testing characterizes silent cardiovascular abnormalities in asymptomatic pediatric cancer survivors. *Pediatr Cardiol*. 2023;44(2):344–353.
35. Camilli M, Skinner R, Iannaccone G, et al. Cardiac imaging in childhood cancer survivors: a state-of-the-art review. *Curr Probl Cardiol*. 2023;48(4), 101544.
36. Corella Aznar EG, Ayerza Casas A, Jiménez Montañés L, Calvo Escribano MÁC, Labarta Aizpún JI, Samper Villagrasa P. Use of speckle tracking in the evaluation of late subclinical myocardial damage in survivors of childhood acute leukaemia. *Int J Cardiovasc Imaging*. 2018;34(9):1373–1381.
37. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2014;27(9):911–939.
38. Li VW yi, So EK fung, Wong WH sang, Cheung Y fai. myocardial deformation imaging by speckle-tracking echocardiography for assessment of cardiotoxicity in children during and after chemotherapy: a systematic review and meta-analysis. *J Am Soc Echocardiogr*. 2022;35(6):629–656.
39. Mertens L, Singh G, Armenian S, et al. Multimodality imaging for cardiac surveillance of cancer treatment in children: recommendations from the American Society of Echocardiography. *J Am Soc Echocardiogr*. 2023;36(12):1227–1253.
40. Azzam M, Wasef M, Khalaf H, Al-Habbaa A. 3D-based strain analysis and cardiotoxicity detection in cancer patients received chemotherapy. *BMC Cancer*. 2023; 23(1):760.
41. Ylänen K, Poutanen T, Savikurki-Heikkilä P, Rinta-Kiikka I, Eerola A, Vettenranta K. Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. *J Am Coll Cardiol*. 2013;61(14):1539–1547.
42. Foulkes S, Costello BT, Howden EJ, et al. Exercise cardiovascular magnetic resonance reveals reduced cardiac reserve in pediatric cancer survivors with impaired cardiopulmonary fitness. *J Cardiovasc Magn Reson*. 2020;22(1):64.
43. Jordan JH, Todd RM, Vasu S, Hundley WG. Cardiovascular magnetic resonance in the oncology patient. *JACC Cardiovasc Imaging*. 2018;11(8):1150–1172.
44. Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: Associations With Long-Term Echocardiographic Outcomes. *J Clin Oncol*. 2012;30(10):1042–1049.
45. Armenian SH, Gelehrter SK, Vase T, et al. Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors. *Clin Cancer Res*. 2014;20(24): 6314–6323.
46. Sherief LM, Kamal AG, Khalek EA, Kamal NM, Soliman AAA, Esh AM. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children. *Hematology*. 2012;17(3):151–156.
47. Aggarwal S, Pettersen MD, Bhambhani K, Gurczynski J, Thomas R, L'Ecuyer T. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. *Pediatr Blood Cancer*. 2007;49(6):812–816.
48. Michel L, Mincu RI, Mrotzek SM, et al. Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer—a meta-analysis. *ESC Heart Fail*. 2020;7(2): 423–433.
49. Chen C, Li G, Liu YD, Gu YJ. A new D-dimer cutoff value to improve the exclusion of deep vein thrombosis in cancer patients. *Asian Pac J Cancer Prev*. 2014;15 (4):1655–1658.
50. Joolharzadeh P, Rodriguez M, Zaghlol R, et al. Recent advances in serum biomarkers for risk stratification and patient management in cardio-oncology. *Curr Cardiol Rep*. 2023;25(3):133–146.
51. Leger KJ, Leonard D, Nielson D, de Lemos JA, Mammen PPA, Winick NJ. Circulating microRNAs: potential markers of cardiotoxicity in children and young adults treated with anthracycline chemotherapy. *J Am Heart Assoc*. 2017;6(4).
52. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. In: van Dalen EC, ed. *Cochrane Database of Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd; 2008.
53. Armenian SH, Lacchetti C, Lenihan D. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american society of clinical oncology clinical practice guideline summary. *J Oncol Pract*. 2017;13(4):270–275.
54. Asselin BL, Devidas M, Chen L, et al. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-hodgkin lymphoma: a report of the children's oncology group randomized trial pediatric oncology group 9404. *J Clin Oncol*. 2016;34(8):854–862.
55. Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. *J Clin Oncol*. 1996;14(2):362–372.
56. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. *Lancet Oncol*. 2010;11(10):950–961.
57. Chow EJ, Aggarwal S, Doody DR, et al. Dexrazoxane and long-term heart function in survivors of childhood cancer. *J Clin Oncol*. 2023;41(12):2248–2257.
58. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. *J Clin Oncol*. 2004;22(5):820–828.

59. Thavendiranathan P, Houbois C, Marwick TH, et al. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. *Eur Heart J Cardiovasc Pharmacother*. 2023;9(6):515–525.
60. Armenian SH, Hudson MM, Lindenfeld L, et al. Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial. *Lancet Oncol*. 2024;25(2):235–245.
61. Friedman DN, Tonorezos ES, Cohen P. Diabetes and metabolic syndrome in survivors of childhood cancer. *Horm Res Paediatr*. 2019;91(2):118–127.
62. Pluimakers V, Fiocco M, van Atteveld J, et al. Metabolic syndrome parameters, determinants, and biomarkers in adult survivors of childhood cancer: protocol for the Dutch childhood cancer survivor study on metabolic syndrome (Dutch LATER METS). *JMIR Res Protoc*. 2021;10(1):e21256.
63. Khondker A, Groff M, Nunes S, et al. KIdney aNd blooD prESsure ouTcomes in childhood cancer survivors: description of clinical research protocol of the KINDEST-CCS study. *Can J Kidney Health Dis*. 2022;9, 205435812211301.
64. Adams SC, Herman J, Lega IC, et al. Young adult cancer survivorship: recommendations for patient follow-up, exercise therapy, and research. *JNCI Cancer Spectr*. 2021;5(1).
65. Esbenshade AJ, Ness KK. Dietary and exercise interventions for pediatric oncology patients: the way forward. *JNCI Monographs*. 2019;2019(54):157–162.
66. Faber J, Wingerter A, Neu MA, et al. Burden of cardiovascular risk factors and cardiovascular disease in childhood cancer survivors: data from the German CVSS-study. *Eur Heart J*. 2018;39(17):1555–1562.
67. Lipshultz ER, Chow EJ, Doody DR, et al. Cardiometabolic risk in childhood cancer survivors: a report from the children's oncology group. *Cancer Epidemiol Biomarkers Prev*. 2022;31(3):536–542.
68. Berkman AM, Lakoski SG. Treatment, behavioral, and psychosocial components of cardiovascular disease risk among survivors of childhood and young adult cancer. *J Am Heart Assoc*. 2015;4(4).
69. Chow EJ, Chen Y, Armstrong GT, et al. Underdiagnosis and undertreatment of modifiable cardiovascular risk factors among survivors of childhood cancer. *J Am Heart Assoc*. 2022;11(12).
70. Florin TA, Fryer GE, Miyoshi T, et al. Physical inactivity in adult survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study. *Cancer Epidemiol Biomarkers Prev*. 2007;16(7):1356–1363.
71. Cox CL, Montgomery M, Oeffinger KC, et al. Promoting physical activity in childhood cancer survivors. *Cancer*. 2009;115(3):642–654.
72. Reiner B, Schmid I, Schulz T, et al. Cardiovascular function and exercise capacity in childhood cancer survivors. *J Clin Med*. 2022;11(3):628.
73. Calvillo-Argüelles O, Jaiswal S, Shlush LI, et al. Connections between clonal hematopoiesis, cardiovascular disease, and cancer. *JAMA Cardiol*. 2019;4(4):380.
74. Armstrong GT, Joshi VM, Ness KK, et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer. *J Am Coll Cardiol*. 2015;65(23):2511–2522.
75. Caru M, Curnier D. The pediatric oncology exercise field speeds up to address important issues regarding chemotherapy-related cardiotoxicity. *Front Pediatr*. 2022;10.
76. LUONGO C, RANDAZZO E, IUGHETTI L, et al. Cardiometabolic risk in childhood cancer survivors. *Minerva Pediatrics*. 2022;73(6).
77. Steinberger J, Sinaiko AR, Kelly AS, et al. Cardiovascular risk and insulin resistance in childhood cancer survivors. *J Pediatr*. 2012;160(3):494–499.
78. Meacham LR, Chow EJ, Ness KK, et al. Cardiovascular risk factors in adult survivors of pediatric cancer—a report from the childhood cancer survivor study. *Cancer Epidemiol Biomarkers Prev*. 2010;19(1):170–181.
79. Rueegg CS, Michel G, Wengenroth L, von der Weid NX, Bergstraesser E, Kuehni CE. Physical performance limitations in adolescent and adult survivors of childhood cancer and their siblings. *PLoS ONE*. 2012;7(10):e47944.
80. Rueegg CS, von der Weid NX, Rebholz CE, et al. Daily physical activities and sports in adult survivors of childhood cancer and healthy controls: a population-based questionnaire survey. *PLoS ONE*. 2012;7(4):e34930.
81. Grydeland M, Bratteteig M, Rueegg CS, et al. Physical activity among adolescent cancer survivors: the PACCS study. *Pediatrics*. 2023;152(3).
82. Raghuveer G, Hartz J, Lubans DR, et al. Cardiorespiratory fitness in youth: an important marker of health: a scientific statement from the American Heart Association. *Circulation*. 2020;142(7).
83. Ruiz JR, Huybrechts I, Cuenca-García M, et al. Cardiorespiratory fitness and ideal cardiovascular health in European adolescents. *Heart*. 2015;101(10):766–773.
84. Nielsen MKF, Christensen JF, Frandsen TL, et al. Effects of a physical activity program from diagnosis on cardiorespiratory fitness in children with cancer: a national non-randomized controlled trial. *BMC Med*. 2020;18(1):175.
85. Schindera C, Zürcher SJ, Jung R, et al. Physical fitness and modifiable cardiovascular disease risk factors in survivors of childhood cancer: A report from the SURfit study. *Cancer*. 2021;127(10):1690–1698.
86. Bucciarelli V, Bianco F, Di Blasio A, et al. Cardiometabolic profile, physical activity, and quality of life in breast cancer survivors after different physical exercise protocols: a 34-month follow-up study. *J Clin Med*. 2023;12(14):4795.
87. Bucciarelli V, Bianco F, Mucedola F, et al. Effect of adherence to physical exercise on cardiometabolic profile in postmenopausal women. *Int J Environ Res Public Health*. 2021;18(2):656.
88. Järvelä LS, Kemppainen J, Niinikoski H, et al. Effects of a home-based exercise program on metabolic risk factors and fitness in long-term survivors of childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2012;59(1):155–160.
89. Tonorezos ES, Robien K, Eshelman-Kent D, et al. Contribution of diet and physical activity to metabolic parameters among survivors of childhood leukemia. *Cancer Causes Control*. 2013;24(2):313–321.
90. Slater ME, Steinberger J, Ross JA, et al. Physical activity, fitness, and cardiometabolic risk factors in adult survivors of childhood cancer with a history of hematopoietic cell transplantation. *Biol Blood Marrow Transplant*. 2015;21(7):1278–1283.
91. Slater ME, Ross JA, Kelly AS, et al. Physical activity and cardiovascular risk factors in childhood cancer survivors. *Pediatr Blood Cancer*. 2015;62(2):305–310.
92. Kang DW, Wilson RL, Christopher CN, et al. Exercise cardio-oncology: exercise as a potential therapeutic modality in the management of anthracycline-induced cardiotoxicity. *Front Cardiovasc Med*. 2022;8.
93. Bratteteig M, Rueegg CS, Raastad T, et al. Physical activity, fitness, and cardiovascular disease risk in adolescent childhood cancer survivors compared to controls: the physical activity in childhood cancer survivors study. *J Adolesc Young Adult Oncol*. 2024;13(2):338–346.
94. Mizrahi D, Wakefield CE, Simar D, et al. Barriers and enablers to physical activity and aerobic fitness deficits among childhood cancer survivors. *Pediatr Blood Cancer*. 2020;67(7).
95. Jones LW, Liu Q, Armstrong GT, et al. Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the childhood cancer survivor study. *J Clin Oncol*. 2014;32(32):3643–3650.
96. Rueegg CS, Zürcher SJ, Schindera C, et al. Effect of a 1-year physical activity intervention on cardiovascular health in long-term childhood cancer survivors—a randomised controlled trial (SURfit). *Br J Cancer*. 2023;129(8):1284–1297.
97. Leerink JM, de Baat EC, Feijen EAM, et al. Cardiac disease in childhood cancer survivors. *JACC CardioOncol*. 2020;2(3):363–378.
98. Hudson MM, Bhatia S, Casillas J, et al. Long-term follow-up care for childhood, adolescent, and young adult cancer survivors. *Pediatrics*. 2021;148(3).
99. Kesting S, Giordano U, Weil J, et al. Association of European Paediatric and Congenital Cardiology practical recommendations for surveillance and prevention of cardiac disease in childhood cancer survivors: the importance of physical activity and lifestyle changes From the Association of European Paediatric and Congenital Cardiology Working Group Sports Cardiology, Physical Activity and Prevention, Working Group Adult Congenital Heart Disease, Working Group Imaging and Working Group Heart Failure. *Cardiol Young*. 2024;34(2):250–261.
100. Braam KI, van der Torre P, Takken T, Veening MA, van Dulmen-den Broeder E, Kaspers GJ. Physical exercise training interventions for children and young adults during and after treatment for childhood cancer. *Cochrane Database System Rev*. 2016;2017(3).
101. Bourdon A, Grandy SA, Keats MR. Aerobic exercise and cardiopulmonary fitness in childhood cancer survivors treated with a cardiotoxic agent: a meta-analysis. *Support Care Cancer*. 2018;26(7):2113–2123.
102. Jones LW, Liang Y, Pituskin EN, et al. Effect of exercise training on peak oxygen consumption in patients with cancer: a meta-analysis. *Oncologist*. 2011;16(1):112–120.

103. Järvelä LS, Niinikoski H, Heinonen OJ, Lähteenmäki PM, Arola M, Kemppainen J. Endothelial function in long-term survivors of childhood acute lymphoblastic leukemia: Effects of a home-based exercise program. *Pediatr Blood Cancer*. 2013;60(9):1546–1551.
104. Järvelä LS, Saraste M, Niinikoski H, et al. Home-based exercise training improves left ventricle diastolic function in survivors of childhood all: a tissue doppler and velocity vector imaging study. *Pediatr Blood Cancer*. 2016;63(9):1629–1635.
105. Long TM, Rath SR, Wallman KE, et al. Exercise training improves vascular function and secondary health measures in survivors of pediatric oncology related cerebral insult. *PLoS ONE*. 2018;13(8), e0201449.
106. Morales JS, Santana-Sosa E, Santos-Lozano A, et al. Inhospital exercise benefits in childhood cancer: a prospective cohort study. *Scand J Med Sci Sports*. 2020;30(1):126–134.
107. Smith WA, Ness KK, Joshi V, Hudson MM, Robison LL, Green DM. Exercise training in childhood cancer survivors with subclinical cardiomyopathy who were treated with anthracyclines. *Pediatr Blood Cancer*. 2014;61(5):942–945.
108. Sharkey AM, Carey AB, Heise CT, Barber G. Cardiac rehabilitation after cancer therapy in children and young adults. *Am J Cardiol*. 1993;71(16):1488–1490.
109. WHO Guidelines On Physical Activity And Sedentary Behaviour.
110. Kendall SJ, Langley JE, Aghdam M, et al. The Impact of exercise on cardiotoxicity in pediatric and adolescent cancer survivors: a scoping review. *Curr Oncol*. 2022;29(9):6350–6363.
111. Rapti C, Dinas PC, Chryssanthopoulos C, Mila A, Philippou A. Effects of exercise and physical activity levels on childhood cancer: an umbrella review. *Healthcare*. 2023;11(6):820.
112. Khaleqi-Sohi M, Sadria G, Ghalibafian M, Khademi-Kalantari K, Irannejad S. The effects of physical activity and exercise therapy on pediatric brain tumor survivors: a systematic review. *J Bodyw Mov Ther*. 2022;30:1–9.
113. Mizrahi D, Wakefield CE, Fardell JE, et al. Distance-delivered physical activity interventions for childhood cancer survivors: A systematic review and meta-analysis. *Crit Rev Oncol Hematol*. 2017;118:27–41.
114. Morales JS, Valenzuela PL, Herrera-Olivares AM, et al. What are the effects of exercise training in childhood cancer survivors? A systematic review. *Cancer Metastasis Rev*. 2020;39(1):115–125.
115. Santos S da S, Moussalle LD, Heinzmann-Filho JP. Effects of physical exercise during hospitalization in children and adolescents with cancer: a systematic review. *Revista Paulista de Pediatria*. 2021:39.
116. Wogksch MD, Goodenough CG, Finch ER, Partin RE, Ness KK. Physical activity and fitness in childhood cancer survivors: a scoping review. *Aging Cancer*. 2021;2(4):112–128.
117. Brown MC, Araújo-Soares V, Skinner R, et al. Using qualitative and co-design methods to inform the development of an intervention to support and improve physical activity in childhood cancer survivors: a study protocol for BEing Active after ChildhOod caNcer (BEACON). *BMJ Open*. 2020;10(12), e041073.
118. Okada M, Meeske KA, Menteer J, Freyer DR. Exercise recommendations for childhood cancer survivors exposed to cardiotoxic therapies. *J Pediatr Oncol Nurs*. 2012;29(5):246–252.
119. De Caro E, Fioredda F, Calevo M, et al. Exercise capacity in apparently healthy survivors of cancer. *Arch Dis Child*. 2005;91(1):47–51.
120. Elshahat S, Treanor C, Donnelly M. Factors influencing physical activity participation among people living with or beyond cancer: a systematic scoping review. *Int J Behav Nutr Phys Act*. 2021;18(1):50.
121. Hoffman MC, Mulrooney DA, Steinberger J, Lee J, Baker KS, Ness KK. Deficits in physical function among young childhood cancer survivors. *J Clin Oncol*. 2013;31(22):2799–2805.
122. van Kalsbeek RJ, van der Pal HJH, Kremer LCM, et al. European PanCareFollowUp recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer. *Eur J Cancer*. 2021;154:316–328.
123. Trost SG, Loprinzi PD. Parental influences on physical activity behavior in children and adolescents: a brief review. *Am J Lifestyle Med*. 2011;5(2):171–181.
124. Cheung AT, Li WHC, Ho LLK, Chan GCF, Lam HS, Chung JOK. Efficacy of mobile instant messaging–delivered brief motivational interviewing for parents to promote physical activity in pediatric cancer survivors. *JAMA Netw Open*. 2022;5(6), e2214600.
125. Mattioli AV, Gallina S. Early cardiovascular prevention: the crucial role of nurse-led intervention. *BMC Nurs*. 2023;22(1):347.
126. Cheung AT, Li WHC, Ho LLK, Ho KY, Chan GCF, Chung JOK. Physical activity for pediatric cancer survivors: a systematic review of randomized controlled trials. *J Cancer Survivor*. 2021;15(6):876–889.
127. Bouwman E, Hermens RPMG, Brown MC, et al. Person-centred online lifestyle coaching in childhood, adolescent, and young adult cancer survivors: protocol of the multicentre PanCareFollowUp lifestyle intervention feasibility study. *Pilot Feasibility Stud*. 2022;8(1):260.
128. Bouwman E, Pluijm SMF, Stollman I, et al. Perceived barriers and facilitators to health behaviors in European childhood cancer survivors: A qualitative PanCareFollowUp study. *Cancer Med*. 2023;12(11):12749–12764.
129. Lie HC, Anderssen S, Rueegg CS, et al. The Physical Activity and Fitness in Childhood Cancer Survivors (PACCS) study: protocol for an international mixed methods study. *JMIR Res Protoc*. 2022;11(3):e35838.
130. Bucciarelli V, Mattioli AV, Sciomer S, Moscucci F, Renda G, Gallina S. The impact of physical activity and inactivity on cardiovascular risk across women's lifespan: an updated review. *J Clin Med*. 2023;12(13):4347.
131. Mattioli AV, Coppi F, Bucciarelli V, Gallina S. Cardiovascular risk stratification in young women: the pivotal role of pregnancy. *J Cardiovasc Med*. 2023;24(11):793–797.
132. Mattioli AV, Moscucci F, Sciomer S, et al. Cardiovascular prevention in women: an update by the Italian Society of Cardiology working group on 'Prevention, hypertension and peripheral disease. *J Cardiovasc Med*. 2023;24(Supplement 2):e147–e155.
133. Crowder SL, Buro AW, Stern M. Physical activity interventions in pediatric, adolescent, and young adult cancer survivors: a systematic review. *Support Care Cancer*. 2022;30(6):4635–4649.